Search research articles
Contact Us
Filters
Showing results (21-30 of 63) with videos related to
Page
of 7
Sort By:
Vascular Cell
|
March 4, 2014
Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro
Sergei I Agoulnik, Satoshi Kawano, Noel Taylor, et al.
Plos One
|
July 14, 2017
Feedback activation of AMPK-mediated autophagy acceleration is a key resistance mechanism against SCD1 inhibitor-induced cell growth inhibition
Akito Ono, Osamu Sano, Ken-Ichi Kazetani, et al.
Plos One
|
November 11, 2016
A Novel Selective Inhibitor of Delta-5 Desaturase Lowers Insulin Resistance and Reduces Body Weight in Diet-Induced Obese C57BL/6J Mice
Hiroaki Yashiro, Shuichi Takagahara, Yumiko Okano Tamura, et al.
Journal of Thyroid Research
|
October 9, 2014
Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models
Osamu Tohyama, Junji Matsui, Kotaro Kodama, et al.
Cancer Science
|
October 29, 2015
Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models
Ken Ito, Shusei Hamamichi, Makoto Asano, et al.
ACS Medicinal Chemistry Letters
|
January 16, 2015
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization
Kiyoshi Okamoto, Megumi Ikemori-Kawada, Anja Jestel, et al.
Diabetes
|
August 28, 2004
Increased serum leptin protects from adiposity despite the increased glucose uptake in white adipose tissue in mice lacking p85alpha phosphoinositide 3-kinase
Yasuo Terauchi, Junji Matsui, Junji Kamon, et al.
Biochemical and Biophysical Research Communications
|
April 5, 2019
Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades
Taisuke Hoshi, Saori Watanabe Miyano, Hideki Watanabe, et al.
Cancer Science
|
January 21, 2017
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
Masahiro Matsuki, Yusuke Adachi, Yoichi Ozawa, et al.
Anticancer Research
|
June 1, 2018
Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms
Makoto Asano, Junji Matsui, Murray J Towle, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 63) with videos related to
Sort By:
Page
of 7
Vascular Cell
|
March 4, 2014
Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro
Sergei I Agoulnik, Satoshi Kawano, Noel Taylor, et al.
Plos One
|
July 14, 2017
Feedback activation of AMPK-mediated autophagy acceleration is a key resistance mechanism against SCD1 inhibitor-induced cell growth inhibition
Akito Ono, Osamu Sano, Ken-Ichi Kazetani, et al.
Plos One
|
November 11, 2016
A Novel Selective Inhibitor of Delta-5 Desaturase Lowers Insulin Resistance and Reduces Body Weight in Diet-Induced Obese C57BL/6J Mice
Hiroaki Yashiro, Shuichi Takagahara, Yumiko Okano Tamura, et al.
Journal of Thyroid Research
|
October 9, 2014
Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models
Osamu Tohyama, Junji Matsui, Kotaro Kodama, et al.
Cancer Science
|
October 29, 2015
Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models
Ken Ito, Shusei Hamamichi, Makoto Asano, et al.
ACS Medicinal Chemistry Letters
|
January 16, 2015
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization
Kiyoshi Okamoto, Megumi Ikemori-Kawada, Anja Jestel, et al.
Diabetes
|
August 28, 2004
Increased serum leptin protects from adiposity despite the increased glucose uptake in white adipose tissue in mice lacking p85alpha phosphoinositide 3-kinase
Yasuo Terauchi, Junji Matsui, Junji Kamon, et al.
Biochemical and Biophysical Research Communications
|
April 5, 2019
Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades
Taisuke Hoshi, Saori Watanabe Miyano, Hideki Watanabe, et al.
Cancer Science
|
January 21, 2017
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
Masahiro Matsuki, Yusuke Adachi, Yoichi Ozawa, et al.
Anticancer Research
|
June 1, 2018
Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms
Makoto Asano, Junji Matsui, Murray J Towle, et al.
Page
of 7